Chinese Journal of Tissue Engineering Research ›› 2012, Vol. 16 ›› Issue (32): 6076-6080.doi: 10.3969/j.issn.2095-4344.2012.32.035

Previous Articles    

HLA haploidentical and matched allogeneic hematopoietic stem cell transplantation in treatment of hematological malignancies

Wan Ding-ming1, Shao Yun-li1, Qin Tong2, Zhang Su-ping1, Xie Xin-sheng1, Sun Ling1, Sun Hui1, Bian Zhi-lei1   

  1. 1Department of Hematology, First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China;
    2Department of Hematology and Oncology, Huaihe Hospital of Henan University, Kaifeng 475000, Henan Province, China
  • Received:2011-12-08 Revised:2012-02-03 Online:2012-08-05 Published:2012-08-05
  • About author:Wan Ding-ming☆, M.D., Professor, Chief physician, Master’s supervisor, Department of Hematology, First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China wwddmm@vip.sina.

PDF

632

Abstract:

BACKGROUND: Allogeneic hematopoietic stem cell transplantation (HSCT) is a very effective method in the treatment of hematologic malignancies. The haploidentical HSCT can expand the application of transplantation, and is also an important option for the patients who need a salvage transplantation without a HLA-matched donor.
OBJECTIVE: To compare the therapeutic effects of HLA haploidentical and sibling HLA-matched allogeneic HSCT in the treatment of hematologic malignancies.
METHODS: The clinical outcomes of 79 patients with hematologic malignancies who received allogeneic HSCT, including 26 patients with related HLA-mismatched donors and 53 patients with HLA-matched sibling were retrospectively analyzed. The incidence of graft versus host disease (GVHD), recurrence rate, and 2-year survival rate were compared between HLA-haploidentical and HLA-matched cohorts.
RESULTS AND CONCLUSION: 78 patients achieved full engraftment, but a patient died of severe infection without engraftment at 28 days after transplantation. There was no significant difference in incidence of GVHD, incidence of relapse and 2-year disease-free survival (DFS) between HLA-haploidentical and HLA-matched cohorts (P > 0.05). The incidence of GVHD in HLA-haploidentical cohorts was significantly higher than in HLA-matched cohorts (P < 0.05), and 2-year overall survival was lower (P < 0.05) than the latter. The results suggested that the safety and effect of haploidentical HSCT with modified conditioning regimen were similar to HLA-matched HSCT for hematologic malignancies. Haploidentical HSCT is a safe and feasible approach in the treatment of hematologic malignancies without a HLA-matched related or unrelated donor.

CLC Number: